CorVista System with PH Add-On vs cmAngio®
AI Verdict
Choose CorVista System with PH Add-On if…
Choose the CorVista System with PH Add-On if you require a rapid, non-invasive, point-of-care diagnostic solution for assessing coronary artery disease and pulmonary hypertension. This tool is ideal for situations where immediate results are crucial and traditional invasive or time-consuming diagnostic methods are not preferred or readily available, as it requires no radiation, contrast agents, or extensive patient preparation.
View CorVista System with PH Add-On →Choose cmAngio® if…
Choose cmAngio® if you aim to enhance cardiovascular risk assessment for women by leveraging existing mammography data. This AI software is best suited for integrating into breast imaging workflows to automatically detect and visualize Breast Arterial Calcifications (BACs), providing valuable insights into a patient's cardiovascular health without additional procedures or radiation exposure.
View cmAngio® →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | CorVista System with PH Add-On | cmAngio® |
|---|---|---|
| Pricing | Unknown | Paid, out-of-pocket |
| Deployment | Cloud-based, point-of-care system. | Cloud-based, integrates with any DICOM-compliant viewer |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
CorVista System with PH Add-OnTool A (CorVista System) offers superior patient usability by providing a non-invasive, point-of-care diagnostic that requires no radiation, contrast agents, injections, fasting, or exercise, with rapid results available within minutes. The system is designed to be easy for a medical assistant to operate, significantly enhancing the patient experience and streamlining clinical workflow.
Clinical Value
CorVista System with PH Add-OnBoth tools are FDA-cleared and offer significant clinical value. However, Tool A (CorVista System) provides direct, rapid diagnosis for critical and often life-threatening conditions like coronary artery disease and pulmonary hypertension, with high sensitivity and specificity, and has received an FDA Breakthrough Device Designation. This direct diagnostic capability for acute diseases offers a more immediate and impactful clinical value compared to Tool B's risk stratification.
Pricing & Value
CorVista System with PH Add-OnWhile both tools lack transparent public pricing, Tool A (CorVista System) is explicitly offered under a 'medical-device-as-a-service model' and has published cost-economic analyses demonstrating significant savings to the healthcare system by preventing delays and reducing the need for more expensive care. This provides a clearer, documented value proposition despite the undisclosed price.
Enterprise Readiness
cmAngio®Tool B (cmAngio) demonstrates stronger enterprise readiness through explicit claims of being 'cybersecure,' 'HIPAA-compliant,' and offering 'quick and easy installation' (less than an hour) with compatibility across 'any DICOM-compliant viewer.' Its reported adoption at 'hundreds of sites across the US' further validates its practical integration and scalability within healthcare enterprises.
Innovation
CorVista System with PH Add-OnBoth tools are innovative, but Tool A (CorVista System) introduces a more disruptive innovation by offering a completely non-invasive, point-of-care AI diagnostic platform for complex cardiovascular diseases without traditional burdens like radiation or injections. Its FDA Breakthrough Device Designation for pulmonary hypertension underscores its novel approach and potential to transform diagnostic pathways.
Support & Docs
TieNeither the provided structured facts nor the web search results offer sufficient specific information regarding the scope, availability, or quality of support services or comprehensive documentation for either Tool A or Tool B. Therefore, a definitive winner cannot be determined for this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | CorVista System with PH Add-On | cmAngio® |
|---|---|---|
| Name | CorVista System with PH Add-On | cmAngiou00ae |
| Company | Analytics for Life | CureMetrix |
| Description | The CorVista System with PH Add-On is an FDA-cleared, non-invasive, point-of-care AI diagnostic platform for rapid assessment of coronary artery disease and pulmonary hypertension using machine-learned algorithms. | cmAngiou00ae by CureMetrix is FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. |
| Key Features | Non-invasive cardiovascular diagnostics, Point-of-care testing, Machine-learned algorithms for analysis, Analyzes cardiac and hemodynamic signals, No radiation, contrast agents, injections, fasting, or exercise required, Rapid results available within minutes, Secure web portal for physician access to analysis, Modular design with disease-specific add-ons (CAD, PH) | AI-based detection of Breast Arterial Calcifications (BAC), Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams, Provides visualization of BAC location on a scorecard, Enables BAC identification and reporting without additional radiation or procedures, Compatible with any DICOM-compliant viewer, Adjustable operating point to meet clinical goals, Quick and easy installation (less than an hour), Cybersecure and HIPAA-compliant |
| Categories | Cardiology AI, Radiology & Imaging AI | Cardiology AI, OB/GYN AI, Radiology & Imaging AI |
| Specialties | Cardiology, Internal Medicine, Pulmonology | Cardiology, Obstetrics & Gynecology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring CorVista System with PH Add-On and cmAngio®.